Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 11, 2009, Pages 4718-4725

  Drusano, G L ^a   Okusanya, O O ^a   Okusanya, A O ^a   Van Scoy, B ^a   Brown, D L ^a   Fregeau, C ^a   Kulawy, R ^a   Kinzig, M ^b   Sorgel F ^b,c   Heine, H S ^d   Louie, A ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b IBMP Institute for Biomedical and Pharmaceutical Research   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d U S ARMY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN;

ANTHRAX; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL SPORE; BACTERIUM COLONY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; HOLLOW FIBER; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; QUORUM SENSING; VEGETATIVE STAGE;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BACILLUS ANTHRACIS; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; QUINOLINES; SPORES, BACTERIAL;

EID: 70350318143     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00802-09     Document Type: Article

References (9)

1. Clinical and Laboratory Standards Institute. 1999. Document M26-A. Methods for determining bactericidal activity of antimicrobial agents; approved guidelines. Clinical and Laboratory Standards Institute, Wayne, PA.
2. Clinical and Laboratory Standards Institute. 2006. Document M7-A7. Methods for dilutional antimicrobial susceptibility testing for bacteria that grow aerobically; approved standard, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Deziel, M., H. Heine, A. Louie, M. Kao, W. R. Byrne, J. Bassett, L. Miller, K. Bush, M. Kelley, and G. L. Drusano. 2005. Identification of effective antimicrobial regimens for use in humans for the therapy of Bacillus anthracis infections and post-exposure prophylaxis. Antimicrob. Agents Chemother. 49:5099-5106.
4. Heine, H. S., A. Louie, F. Sorgel, J. Bassett, L. Miller, L. J. Sullivan, M. Kinzig-Schippers, and G. L. Drusano. 2007. Comparison of two different protein synthesis inhibitor antibiotics for the therapy of Yersinia pestis delivered by aerosol challenge in a mouse model of pneumonic plague. J. Infect. Dis. 196:782-787.
5. Jones, M. B., R. Jani, D. Ren, T. K. Wood, and M. J. Blaser. 2005. Inhibition of Bacillus anthracis growth and virulence-gene expression by inhibitors of quorum sensing. J. Infect. Dis. 191:1881-1888.
6. Leary, R., R. Jelliffe, A. Schumitzky, and M. Van Guilder. 2001. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p. 389-394. In Proceedings of the 14th IEEE Symposium on Computer-Based Medical Systems. IEEE Computer Society, Bethesda, MD.
7. Louie, A., M. R. Deziel, W. Liu, and G. L. Drusano. 2007. Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy. Antimicrob. Agents Chemother. 51:2661-2667.
8. Louie, A., H. S. Heine, K. Kim, D. L. Brown, B. VanScoy, W. Liu, M. Kinzig-Schippers, F. Sörgel, and G. L. Drusano. 2008. Use of an in vitro model of Bacillus anthracis infection to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance. Antimicrob. Agents Chemother. 52:2486-2496.
9. Sullivan, J. T., M. Woodruff, J. Lettieri, V. Agarwal, G. J. Kroll, P. T. Leese, S. Watson, and A. H. Heller. 1999. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob. Agents Chemother. 43:2793-2797.